Intercept Pharmaceuticals closes $30M Series C financing
11:15 EDT 10 Aug 2012 | CentreWatch
Intercept Pharmaceuticals, a New York-based clinical stage biopharmaceutical company focused on chronic liver diseases, has completed a $30 million Series C preferred stock financing led by OrbiMed Advisors, a global healthcare investment firm, with..
Original Article: Intercept Pharmaceuticals closes $30M Series C financing
More From BioPortfolio on "Intercept Pharmaceuticals closes $30M Series C financing"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
